 How the project intends to progress to a drug approval  The partnership and funding model to enable this  What type of commercialisation plan is envisaged for revenue generation  Alternatively, they may choose the Open Source Drug Discovery route These points cover a lot of detail but some expansion can be made. It is an inefficient use of resources with concomitantly diminished chances of commercial success if ADEV teams deliberately (as opposed to accidental CI oversight) go head-to-head against pharmaceutical companies. This certainly applies to the more crowded therapeutic areas where the available standard-of-care medicines (including generics) have achieved some level of effectiveness (i.e. the medical needs have been met to some extent). However, we can consider the following exceptions ;